Literature DB >> 32840316

Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".

Denise Bernhardt1, Stephanie E Combs1,2,3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32840316      PMCID: PMC7499714          DOI: 10.1093/neuonc/noaa203

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
We thank Borsa et al[1] for the interest in our recently published practice recommendation for the treatment of high-grade glioma patients during the coronavirus disease 2019 (COVID-19) pandemic.[2] We appreciate the positive feedback and valuable comments relative to our study on the role of mitigation strategies and the impact of our own recommendations, especially in light of the immense effect of COVID-19 on Italy, as one of the most affected areas in Europe. Our publication recommended the use of of digital solutions for tumor boards and conferences during the pandemic. It is difficult to give suggestions on how to proceed in detail with the patient flow and the structures in an outpatient clinic, as this is greatly dependent on individual jurisdictional and hospital policies. Borsa et al provide helpful and detailed insights into how hospitals and individual departments can implement those recommendations. For example, they recommend to do telephone interviews 1–2 days ahead of a scheduled appointment to screen for potential COVID-19 related symptoms. They also tried to schedule follow-up MRIs and medical examination on the same day to reduce the flow of patients accessing the facility. Furthermore, patients were encouraged to contact the relevant caregivers by phone or email and were provided digital solutions. This efficient and low-threshold service provides easy access for patients while avoiding unnecessary referrals of symptomatic patients to emergency wards, which are likely hotspots for SARS/CoV-2 infections during the pandemic. In conclusion, we appreciate Borsa’s comments and feedback on our work. Direct feedback and hands-on information from pandemic epicenters are highly relevant as we are still lacking data. Luckily, the available evidence on COVID-19 is increasing rapidly, but this also leads to a highly dynamic situation and we need to regularly reevaluate our recommendation and maybe alter strategies.
  2 in total

1.  Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.

Authors:  Denise Bernhardt; Wolfgang Wick; Stephanie E Weiss; Arjun Sahgal; Simon S Lo; John H Suh; Eric L Chang; Matthew Foote; James Perry; Bernhard Meyer; Peter Vajkoczy; Patrick Y Wen; Christoph Straube; Steffi Pigorsch; Jan J Wilkens; Stephanie E Combs
Journal:  Neuro Oncol       Date:  2020-05-05       Impact factor: 12.300

2.  Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy.

Authors:  Stefano Borsa; Giulio Bertani; Lorenzo Gay; Elena Pirola; Marco Riva; Manuela Caroli
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.